Skip to main content
. 2019 May;16(5):580–588. doi: 10.1513/AnnalsATS.201807-443OC

Table 1.

Baseline characteristics of study participants stratified by computed tomography honeycombing

Characteristics CT Honeycombing Absent (n = 838) CT Honeycombing Present (n = 492)
Age, yr 66.1 (13.2) 68.1 (11.8)
Male 390 (46.5) 270 (54.9)
Race/ethnicity    
 White 636 (75.9) 373 (75.8)
 Black 110 (13.1) 65 (13.2)
 Hispanic 37 (4.4) 27 (5.5)
 Asian 40 (4.8) 20 (4.1)
Ever smoker 329 (39.7) 245 (49.8)
Body mass index, kg/m2 29.8 (6.9) 28.2 (5.7)
Clinical features    
 Crackles 519 (76.7) 352 (84.0)
 Clubbing 74 (8.8) 87 (17.7)
Lung function    
 FVC, % predicted 68.9 (19.4) 65.9 (18.8)
 DlCO, % predicted 52.3 (21.8) 46.1 (19.6)
 Oxygen therapy 228 (27.2) 172 (35.0)
 Immunosuppressive therapy 409 (50.0) 259 (54.0)
CT fibrosis    
 Reticulation 532 (63.5) 328 (66.7)
 Traction bronchiectasis 157 (18.7) 242 (49.2)
Antifibrotic therapy 63 (7.5) 38 (7.7)
Time from CT to ILD diagnosis, mo 3.5 (23.1) 2.6 (24.0)
ILD subcategory    
 Idiopathic pulmonary fibrosis 399 (47.6) 240 (48.8)
 Connective tissue disease–associated ILD 154 (18.4) 111 (22.6)
 Unclassifiable/others 202 (24.1) 81 (16.5)
 Chronic hypersensitivity pneumonitis 83 (9.9) 60 (12.2)

Definition of abbreviations: CT = computed tomography; DlCO = diffusing capacity of the lung for carbon monoxide; FVC = forced vital capacity; ILD = interstitial lung disease; SD = standard deviation.

Total sample size, N = 1,330. Categorical variables presented as n (%); continuous variables presented as mean (SD). Exception for participants: body mass index, n = 1,247; crackles, n = 1,096; clubbing, n = 1,329; FVC, n = 1,265; DlCO, n = 1,191; immunosuppressive therapy, n = 1,302; idiopathic pulmonary fibrosis, n = 639; connective tissue disease–associated ILD, n = 265; chronic hypersensitivity pneumonitis, n = 143; unclassifiable/other ILD, n = 283.